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BACKGROUND Carrion’s disease (CD) is a neglected biphasic illness caused by Bartonella bacilliformis, a Gram-negative 
bacteria found in the Andean valleys. The spread of resistant strains underlines the need for novel antimicrobials against B. 
bacilliformis and related bacterial pathogens.
OBJECTIVE The main aim of this study was to integrate genomic-scale data to shortlist a set of proteins that could serve as 
attractive targets for new antimicrobial discovery to combat B. bacilliformis.
METHODS We performed a multidimensional genomic scale analysis of potential and relevant targets which includes structural 
druggability, metabolic analysis and essentiality criteria to select proteins with attractive features for drug discovery.
FINDINGS We shortlisted seventeen relevant proteins to develop new drugs against the causative agent of Carrion’s disease. 
Particularly, the protein products of fabI, folA, aroA, trmFO, uppP and murE genes, meet an important number of desirable 
features that make them attractive targets for new drug development. This data compendium is freely available as a web server 
(http://target.sbg.qb.fcen.uba.ar/).
MAIN CONCLUSION This work represents an effort to reduce the costs in the first phases of B. bacilliformis drug discovery.
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Bartonella bacilliformis (Bb) is a Gram-negative 
pathogenic bacterium responsible for Carrion’s disease 
(CD) which causes haemolytic anaemia and skin lesions.
(1) This infection is endemic to some areas of Peru, Co-
lombia, and Ecuador. It is mainly associated with pov-
erty, climate changes, and the little financial support it 
receives.(2) This disease has two different clinical phases. 
The early or acute phase (Oroya fever) symptoms include 
fever and profound anaemia and usually show up about 
60 days after infection. This phase is fatal to 40-88% 
of patients without antibiotic intervention and even with 
adequate treatment, the mortality rate can increase to 
9-11%. The chronic phase or Peruvian verruga is charac-
terised by the onset of dermal eruptions known as warts. 
This phase is seldom fatal, but lesions can scar or bleed, 
and eruptions can be accompanied by fever, headache, 
lymphadenopathy, acute joint, and bone pains.(3)
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While research has found that Bb, and another genus’ 
species, are highly susceptible to a wide-set of drugs in vi-
tro, such as beta-lactams (including penicillins and ceph-
alosporins), aminoglycosides and quinolones,(4) antibiotic 
treatment is not always successful in patients. Several 
confounding factors, including patient history, frequent 
secondary infections, and immunosuppression elicit per-
sistent or recurrent bartonellosis despite antibiotic treat-
ment. For decades, Oroya fever has been treated with 
chloramphenicol (due to frequent intercurrent infection 
with Salmonella). Alternative drugs include beta-lactams 
(ampicillin, penicillin G), tetracyclines (doxycycline), 
macrolides (erythromycin, roxithromycin), trimethoprim-
sulfamethoxazole, and fluoroquinolones (norfloxacin, 
ciprofloxacin).(5) Although the second generation fluoro-
quinolone ciprofloxacin is the drug of choice for adults 
in the acute phase of Carrion’s disease, resistance to qui-
nolones produced by mutations or substitutions of amino 
acids in molecular targets were reported.(6) On the other 
hand, mutations conferring resistance to ciprofloxacin, 
rifampin, and erythromycin have been molecularly char-
acterised.(6) The drug of choice for treating the eruptive 
phase of CD is rifampin; however, it has not always been 
successful.(5) Of note is that the chronic phase does not re-
spond to either chloramphenicol or penicillin treatment.(7)
The World Health Organization (WHO) has been 
warning that simple infections treatment is facing an 
alarming crisis in the health system due to the diverse 
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resistant mechanisms emerging and spreading globally 
in the last decades. Despite this critical situation, we 
are facing a low output antibiotic development pipeline 
that, coupled with regulatory challenges and unattractive 
costs, led to many pharmaceutical companies exiting the 
field. The main limitation of traditional high-throughput 
screening (HTS) is that only a limited set of chemicals 
are available in any given HTS library. As this chemi-
cal space limitation would hardly be overcome, new ap-
proaches are urgently needed to deal with the increasing 
problem of bacterial resistance. Nowadays, omic ap-
proaches have created new opportunities for antibiotic 
discovery, aiding the evaluation of protein suitability to 
be used as a drug target, which allows to significantly 
reduce the costs of the initial phases of drug discovery. 
Thus, the initial detection of new targets can be done 
entirely computationally by integrating data and apply-
ing filters to select those with better features for the later 
steps. An example of a filter that can be used to select 
potential targets would be to consider only proteins that 
have an inhibition site with adequate structural character-
istics to bind a drug-like compound. We and others have 
previously used in-silico efforts to select drug targets in 
clinically relevant pathogens such as Streptococcus pneu-
moniae,(8) Mycobacterium tuberculosis,(9) Pseudomonas 
aeruginosa,(10) Klebsiella pneumoniae,(11) Salmonella en-
terica subsp,(12) and many other pathogens. Building upon 
some of this type of data mining works, other researchers 
were able to find successful inhibitors of selected targets, 
such as those acting on quorum-sensing components in P. 
aeruginosa(13) and histidine kinases of S. epidermidis(14) 
and Shigella flexneri.(15) While the application of compu-
tational techniques alone does not envisage a definitive 
identification of drug targets, this approach offers poten-
tial time saving and cost benefits by reducing the search 
space to candidates with increased probability of serving 
as targets for either new or repositioned drugs.
To our knowledge, this is the first report that uses an 
exhaustive application of a multidimensional data inte-
gration strategy to prioritise drug targets in Bb. Combin-
ing several layers of genomic-scale information which 
included genomic, metabolic, and protein structural data 
sources, we were able to describe a set of proteins with 
attractive features for target selection.
MATERIALS AND METHODS
Bacterial strain - Bb USM-LMMB 07 was first iso-
lated in 2011 by our research group in Laboratorio de 
Microbiología Molecular y Biotecnología - Facultad de 
Ciencias Biológicas - Universidad Nacional Mayor de San 
Marcos (UNMSM) - Lima, Perú, during an outbreak in 
Carmen de la Frontera district, Huancabamba province, 
Piura. Its genome was previously sequenced and annotat-
ed by our group.(16) All annotations and sequences for this 
bacterium are available at the BioProject/NCBI (https://
www.ncbi.nlm.nih.gov/assembly/GCF_001624625.1), 
under access number NZ_LQXX01000001.1.
Obtaining B. bacilliformis protein sequences and 
preliminary analysis - All open reading frames (ORFs) 
were derived from the proteome downloaded from the 
Uniprot database (www.uniprot.org, organism code 
UP000076477). All ORFs were analysed with the HM-
MER software (http://hmmer.org/), which assigned 
them to families or domains, grouped according to 
PFAM (https://pfam.xfam.org/) classification.
Generation of models based on structural homology 
- Since no crystallised Bb protein structures were found 
deposited in the Protein Data Bank (PDB) (https://www.
rcsb.org/) homology-based models were built for all pro-
teome sequences using MODELLER (https://salilab.org/
modeller/) when the adequate template was available as 
described before.(9,11,17) Briefly, protein sequences were 
PSI-BLASTed (-num_iterations 3 and -e 1e-05) against 
the UniRef50 (non-redundant sequence database, where 
sequences are grouped with 50% sequence identity, gen-
erated from two previous steps of clusterisation of Uni-
prot database). Once a position-specific scoring matrix 
(PSSM) was obtained, it was used to search against the 
PDB95 (non-redundant PDB proteins with 95% sequence 
identity threshold) using PSI-BLAST with E-value ≤ 10-5 
(-e 1e-05) as a cutoff threshold. Up to five recovered PDB 
structures were used as templates for homology-based 
modeling using MODELLER. MODELLER was used 
without modifying the parameters implemented as de-
fault by the software. Five models per template for each 
Bb protein were built. Models were classified by the 
GA341 score. Only those models with GA341 above 0.7 
and over 60% coverage were retained. At last, one repre-
sentative model which maximises QMEAN Z-score was 
chosen for further analyses. To ensure the good quality 
of the models only those models with QMEAN-Z be-
tween - two and two were kept. With this strategy, we 
were able to build a total of 882 structural models from a 
total of 1143 ORF present in the Bb genome.
Druggability assessment - Druggability is a concept 
used to describe proteins’ ability to bind drug-like com-
pounds, leading to protein modulation in the desired 
way.(17) Druggable proteins should have a well-defined 
pocket with proper physicochemical features to allow 
binding sites prediction. Our group has developed a fast 
method for druggability prediction based on the open-
source algorithm fpocket (http://fpocket.sourceforge.
net/), which combines several physicochemical descrip-
tors to estimate the druggability of the pockets present in 
proteins. Considering the drug score (DS) distribution of 
the protein pockets hosting a drug-like compound in the 
PDB, these pockets were classified into four categories: 
non-druggable (ND) (0.0 ≤ DS <0.2), poorly druggable 
(PD) (0.2 ≤ DS < 0.5), druggable (D) (0.5 ≤ DS < 0.7) and 
highly druggable (HD) (0.7 ≤ DS ≤ 1.0). All proteins for 
which structural models were obtained were subjected 
to this classification (see http://target.sbg.qb.fcen.uba.ar/
patho/user/methodology for details).
Off-target criteria - All Bb USM-LMMB07 proteins 
were submitted to BLASTp analysis against the human 
proteome (NCBI assembly access GCF_000001405.36) 
to identify non-human-homologous targets. Hits with an 
E-value lower than 10−5 and identity of 40% or above 
were discarded, as they can share a high degree of struc-
tural preservation that could produce adverse effects if 
the bacterial protein is used as a target.
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Similarly, protein inhibition of the normal flora is 
likely to result in adverse effects. To mitigate this pos-
sibility, Bb USM-LMMB07 proteins were compared to 
the proteins of the 226 representative microorganisms of 
human intestinal flora sequenced by the Human Micro-
biome Project.(18) BLASTp assessed the number of micro-
biota organisms showing at least one significant match 
to the above-mentioned assessment criterion (E-value ≤ 
10−5, identity ≥ 40%). This is aimed at identifying can-
didate proteins for which the developed drugs show an 
improved selectivity towards the bacterial pathogen, thus 
minimising the impact on the commensal gut microbiota.
Construction of the metabolic network of Bb USM-
LMMB07 - The PathoLogic module from Pathway Tools 
v. 20.0(19) was used to build the Bb metabolic network 
(MN) using the annotated genome as input. With this 
tool, a Pathway/Genome (PGDB) database was created 
containing the predicted reactions and metabolic path-
ways of the organism. The PGDB database was built us-
ing organism taxonomic class = B. bacilliformis, NCBI 
taxonomy ID = 774). This metabolic reconstruction is 
mainly based on the EC number corresponding to each 
enzyme. EC number annotation has been previously 
performed manually during the genomic annotation of 
the Bb USM-LMMB07 strain (https://www.ncbi.nlm.
nih.gov/assembly/GCF_001624625.1).
After manual curation of the metabolic network re-
construction was completed, it was exported in SBML 
format for further analysis. In particular, those reactions 
called “small molecules”, (i. e. reactions which involve 
small compounds) were exported to reduce the complex-
ity of the network when evaluating topological measures 
and choke-point reactions.(20) Once the network was ex-
ported, the frequency at which each of the metabolites 
appeared within the reactions was checked by using an 
in-house Python script. Those compounds appearing 
most frequently within the reactions, and not participat-
ing in the flow of carbon, were considered ubiquitous 
(compounds involved in a significant number of reac-
tions), such as ATP, water and protons. These ubiqui-
tous compounds were subsequently removed from the 
network because they can generate artificial interactions 
within the metabolism.
The resulting metabolic network was represented as 
a reaction graph using Cytoscape_v3.7.0,(21) after trans-
forming the file from the SBML format to sif (simple in-
teraction file), using the same script mentioned above. In 
this representation, nodes represent reactions (i.e., usu-
ally enzymes) and there is an edge between two nodes, 
if a product of a reaction is used as a substrate of the 
reaction that follows. Graph representation allowed us 
to calculate choke-points and topological measures as 
betweenness centrality. Chokepoints are reactions that 
uniquely produce or consume a given product or sub-
strate, respectively. Since it is assumed that the blocking 
of such types of reactions may either lead to the accu-
mulation of a potentially toxic compound in the cell or 
the lack of an essential metabolite, choke-point reactions 
have great significance in drug targeting. The between-
ness centrality of every node was calculated as described 
elsewhere.(17) High values of node betweenness central-
ity from the metabolic perspective, reflects the partici-
pation of a reaction as an intermediary in many other 
transformations, and its blockage would generate dis-
equilibrium in many different pathways.
Data integration and target prioritisation - All pre-
viously calculated data were integrated into our own 
developed platform Target-Pathogen (TP),(17) which in-
cludes a database and a web server for prioritising drug 
targets. Fig. 1 represents the workflow followed for mo-
lecular target prioritisation in Bartonella.
Characterisation of druggable proteins for Bb USM- 
LMMB07 - After target prioritisation, the selected pro-
teins were better characterised by making further analy-
sis. PSORTbv3.0 (https://www.psort.org/), running in 
Bacterial- Gram-negative mode, was used to predict 
subcellular localisation. Gene Ontology terms were ob-
tained from Unpriot KB. Compute pI/Mw(22) was used to 
calculate the theoretical isoelectric point and molecular 
weight. Essentiality analysis was made by blasting the 
selected targets against the Database of Essential Genes 
(DEG) (http://www.essentialgene.org/) for homology 
analysis using BLASTp. The analysis was carried out 
against the DEG database using sequence identity ≥ 
40 % and E-value ≤ 10-5 as the cutoff threshold. DEG 
proteins are classified as essential proteins based on ex-
perimental trials. If an essential homologous protein is 
found for a given protein, it is also likely to be essential 
since functions encoded by essential genes are widely 
conserved in microorganisms.
RESULTS
Bb protein structures USM-LMMB07 are enriched 
in druggable pockets - Our analysis began by classifying 
all obtained domain structures of Bb USM-LMMB07, 
according to their structural druggability. For this pur-
pose, structural domains were first grouped into two 
categories considering only the structural models ob-
tained from our work scheme, since the Protein Data 
Bank (PDB) does not feature any information on experi-
mentally crystallised Bb USM-LMMB07 proteins.
Fig. 1: workflow for the prioritisation of molecular targets in Barton-
ella bacilliformis USM - LMMB07. 
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The first category includes structures modeled from 
a template that was co-crystallised in the presence of an 
inhibitor or a drug-like compound (MD+), thus the pro-
teins of this group are likely to be druggable. The second 
category groups all modeled proteins whose structure 
was resolved from proteins deposited in the PDB with 
no drugs or associated inhibitors present (MD-).
For all structures, all the possible pockets and their 
corresponding drug-related score (DS) were calculated 
using the fpocket software. Using the DS, we classified 
all structures in each category into four drug groups, ac-
cording to the criteria set out above (Fig. 2). The results 
show, as expected, that most of the proteins in the MD+ 
group (almost 70%) have DS Scores higher than 0.5 (Ta-
ble I). Thus, in agreement with previous works(9,11) our 
method can predict to a high degree the likelihood of a 
protein to host a drug-like compound. The first group of 
interest, where novel targets can be found, concerns the 
MD+-HD group (which includes proteins in the MD+ 
group and are also highly druggable), the fact that both 
an association criteria (assignation to MD+) and a struc-
tural criteria (the DS) match is a strong argument for the 
selection of these 110 proteins as drug targets [Supple-
mentary data (Table I)].
Reconstruction of the metabolic network of Bb USM- 
LMMB07 - In the next step of our prioritisation pro-
cedure, we used Pathway tools and manual revision to 
build a comprehensive metabolic network of Bb USM- 
LMMB07 from its annotated genome. A total of 898 
reactions (885 catalysed by enzymes and 13 by trans-
porters) composed the MN. These enzymatic reactions 
are distributed as part of 148 metabolic pathways, which 
groups 1143 proteins.
For comparison, our previously constructed K. pneu-
moniae metabolic network(11) is composed of 1969 reac-
tions with 1847 being enzyme-catalysed and forming 
part of 321 predicted metabolic pathways. This result 
correlates with both genome size.
After the construction of the metabolic network, 
it was exported in systems biology markup language 
(SBML) format for downstream analyses. Reactions in-
volving macromolecules (such as proteins, DNA, and 
RNA) were filtered out, and only reactions involved in 
small-molecules metabolism were considered. The ratio-
nale for this strategy was that since most of the current 
antibiotics target macromolecules (such as ribosomes, 
proteins, lipids), the focus on enzymatic activities that 
are not related to these types of molecules would compre-
hend an unexplored universe suitable for drug discovery.
After exporting the Bb-MN, we calculated the fre-
quency with which all compounds were involved in 
the predicted reactions. The most frequent compounds 
were considered a potential ubiquitous compound (such 
as water, protons, NAD, NADH, ATP, and other cofac-
tors). After manual inspection, a total of 33 compounds 
were filtered out to avoid artificial links creation on the 
reaction graph. Cytoscape v. 3.7.0 was then used for 
graphic visualisation and topological metrics calcula-
tion, particularly the betweenness centrality (BC) (Fig. 
3). The presence of few high-centrality nodes indicates 
that these centers can be of particular importance for 
network cohesion. In such regard, 80 reactions were 
identified with a high degree of centrality (> 0.1), in-
volving 60 proteins. On the other hand, choke-point re-
actions were also identified in the metabolic network 
of Bb USM- LMMB07, i.e. reactions that uniquely 
consume or produce a given compound. A total of 223 
reactions were classified as consumption choke-points, 
while 50 reactions were production choke-points. Be-
sides, 16 reactions were classified as double choke-
point reactions (both consumption and production). 
Choke-point reactions blockade may lead to the lack of 
production of essential metabolites or potentially toxic 
compounds accumulation in the cell; thus, this type of 
reactions have great significance in drug targeting.
TABLE I
Bartonella bacilliformis USM-LMMB07 proteins classified 
according to druggability score (DS)
MD+ MD- Total
Non-druggable 18 (7.46%) 96 (14.97%) 114
Poorly druggable 55 (22.82%) 181 (28.23%) 236
Druggable 58 (24.046%) 159 (24.81%) 217
Highly druggable 110 (45.64%) 205 (31.98%) 315
Total 241 641 882
MD+: structures modeled from crystallised proteins with an 
inhibitor or drug; MD-: structures modeled from crystallised 
proteins without an inhibitor or drug.
Fig. 2: histogram of the druggability score. All Protein Data Bank 
(PDB) structures that bind an inhibitor or drug (blue line), only the 
modeled structures of Bartonella bacilliformis USMLMMB07 from 
crystallised protein structures without the presence of a drug or in-
hibitor (pink line) and only modeled structures of B. bacilliformis 
USM-LMMB07 from protein structures crystallised with a drug or 
inhibitor (black line) are represented. Considering the distribution of 
the score (DS) of the pockets of proteins housing a drug-like com-
pound in the DBP, the pockets were classified into four categories: 
non-druggable (0.0 ≤ DS < 0.2), poorly druggable (0.2 ≤ DS < 0.5), 
druggable (0.5 ≤ DS < 0.7) and highly druggable (0.7 ≤ DS ≤ 1.0). The 
curves in Fig. 2 describe a density function in which the curves are 
fitted to a frequency histogram. It is important to note that in no case 
the druggability score is less 0 or greater than 1.
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Integration of metabolic data, druggability infor-
mation, and off-target criteria make it possible to iden-
tify and prioritise potential molecular targets in drug 
development against B. bacilliformis - All previously 
calculated data was integrated into Target-Pathogen.(17) 
To obtain a set of proteins that fulfill different features 
that make them attractive for drug discovery projects, 
such as structural druggability, off-targeting, essential-
ity, and the metabolic role we apply a set of filters (Fig. 
4). First, all those proteins for which a representative 
structural model could not be obtained were discard-
ed; only 882 out of the 1143 proteins making up the Bb 
USM-LMMB07 proteome met this requirement. Sub-
sequently, proteins with close homologs in the human 
genome and at least one-third of the genomes of the gut 
microbiome were ruled out to minimise the chances of 
cross-interference (and toxicity) of a drug with human 
host proteins. Then, all those proteins that were not 
highly druggable (DS < 0.7) were filtered out and 235 
highly druggable proteins with no close homologs in 
the human genome and its microbiome were kept [Sup-
plementary data (Table II)]. Afterward, we further 
filter these proteins by taking into account its impor-
tance from the metabolic point of view. In this sense, we 
kept only those proteins involved in high centrality and 
choke-point reactions. The resulting 17 proteins (Table 
II) harbor high potential for drug targeting.
At last, special attention was paid to those proteins 
for which there is at least one crystal structure, of an-
other protein from the same PFAM domain that was 
crystallised in the presence of an inhibitor or drug-like 
compound. The proteins of this group are even more 
likely to be druggable since both, an association criteria 
(exist a protein of the same PFAM family that was co-
crystallised with drugs) and a structural criteria (DS > 
0.7) match. Moreover, in six (FabI, FolA, AroA, TrmFO, 
UppP, MurE) of a total of seven proteins that fulfill these 
criteria, the predicted druggable pocket overlaps with 
the site where the drug binds the protein in the co-cryst-
allised structure (Fig. 5). Table III shows the six proteins 
that fulfill all the previously described criteria and there-
fore are attractive to be used as targets in drug develop-
ment against B. bacilliformis.
Bartonella bacilliformis targets characterisation - 
Various layers of information were combined, includ-
ing whole-structural, metabolic, and genomic data that 
allowed a shortlisting of target proteins with charac-
teristics from a druggability standpoint. The six high-
Fig. 3: metabolic network of Bartonella bacilliformis USM-LMMB07 represented as a reaction graph. Nodes represent reactions in the network, 
and there is an edge between two nodes when the product of a reaction is used as a substrate in the next reaction. The node size is proportional 
to the betweenness centrality, and the MetaCyc access numbers (http://metacyc.org) are displayed for the central reactions involving the final 
six priority proteins.
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lighted proteins are druggable, don’t have close homo-
logs in the human genome, and are relevant from the 
metabolic point of view.
To further characterise these proteins, we analysed 
their essentiality, ontology (molecular function and the 
biological processes they perform), subcellular localisa-
tion, isoelectric point, and molecular weight (Table III).
The protein product of fabI is an enoyl-[acyl-carrier-
protein] reductase and was found to be located in the 
cytoplasmic membrane. This protein develops fatty acid 
biosynthesis processes in the bacterium. The homology 
analysis through BLASTp against the DEG database 
shows a high degree of similarity to Sphingomonas wit-
tichii RW1 and Caulobacter crescentus FabI (identity = 
60% and 52.89, E-value = 3.63e-109 and E-value of 1.23e-97 
respectively). This protein was also reported to be essen-
tial in many other bacteria such as E. coli and M. tuber-
culosis.(23) In this sense, likely, Bb fabI is also essential 
since functions encoded by essential genes are broadly 
conserved in microorganisms. Dihydrofolate reductase 
(DHFR) FolA is a protein with binding NADP activity 
that participates in the metabolism of drugs, in the bio-
synthetic process of amide, and the biosynthetic process 
tetrahydrofolate. PSORTb analysis reveals that FolA is 
found in the cytoplasm. Protein search using DEG re-
veals that there are essential genes, homologous to Bb 
folA (identity > 40% and E-value = 1.14e-41), present in 
more than ten different organisms, such as Caulobacter 
crescentus and P. aeruginosa.
3-phosphoshikimate 1-carboxyvinyltransferase AroA; 
it is also located in the cytoplasm of B. bacilliformis. This 
protein intervenes in aromatic amino acids and cho-
rismate biosynthesis as revealed by ontology analysis. 
High identity was found against Rhodopseudomonas 
palustris CGA009 and C. crescentus AroA (53.3% and 
50.9% respectively). As this protein is essential in both 
bacteria, it may also be essential for Bartonella. Protein 
FADH(2)-oxidising methylenetetrahydrofolate--tRNA-
(uracil(54)-C(5))-methyltransferase (TrmFO) is involved 
in tRNA processing, performs methyltransferase activ-
ity and participates in the binding of flavin adenine di-
nucleotide. This protein was found to be located in the 
cytoplasm. Staphylococcus aureus N315 trmFO (gid) 
essential gene was found to be homologous to this Bb 
protein (identity=48% and E-value=2.98e-134). Undeca-
prenyl-diphosphatase UppP is an integral protein of B. 
bacilliformis cytoplasmic membrane. This protein has 
been reported as involved in the synthesis of the car-
rier lipid undecaprenyl phosphate that is essential for the 
biosynthesis of peptidoglycan in other bacterial species. 
The enzyme catalyses the dephosphorylation of unde-
caprenyl diphosphate (UPP). The reaction product is a 
lipid molecule, that transports the peptidoglycan precur-
sors from the cytoplasm to the periplasm through the 
cytoplasmic membrane. However, we did not identify 
homologous genes in DEG. The last prioritised protein 
is the cytoplasmic UDP-N-acetylmuramoyl-L-alanyl-
D-glutamate-2, 6-diaminopimelate ligase (MurE). This 
protein is involved in the cell cycle, the biosynthetic pro-
cess of peptidoglycan, cell division, and cell wall organ-
isation. After performing the homology analysis against 
the DEG database, we noted that it presents an identity 
greater than 50% with the essential proteins of Agrobac-
terium fabrum str. C58 and R. palustris CGA009 (E-val-
ue = 0.0 and 4.54e-146 respectively). It is thus inferred that 
it may be essential for Bartonella’s survival.
DISCUSSION
In this work, we make an integrative analysis frame-
work for protein target prioritisation using as model 
organism B. bacilliformis strain USM- LMMB07, col-
lected in 2011 in northern Perú (Huancabamba, Piura) 
and identified as the causal agent of Oroya fever. Differ-
ent layers of omic information were combined, including 
Fig. 4: general scheme of the prioritisation process in Bartonella bacilliformis USMLMMB07 using Target-Pathogen filters.
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Fig. 5: the structures correspond to the six proteins with the best characteristics to be used as possible molecular targets. Green represents the 
most druggable pocket in each of the proteins. (A) folA; (B) murE; (C) aroA; (D) trmFO; (E) uppP; (F) fabI.
genomic, structural, and metabolic data which allowed 
a shortlisting of targets with desirable characteristics 
from a druggability point of view. Out of 1143 predicted 
proteins that form the proteome of Bb USM- LMMB07, 
we obtained 882 structural models, and we could pre-
dict high druggable pockets for 235 of them. Metabolic 
network reconstruction of this strain allowed metabolic 
complement and enzymatic activities identification per-
formed by Bb, as well as important topological metrics 
in the metabolic network. This information allowed us 
to contextualise functional aspects of the proteins iden-
tified as promising targets. All this information, along 
with other genomic features calculated for each protein, 
were loaded into an openly available web-server (Target 
Pathogen),(17) that allows easy retrieval of any of the gen-
erated data, along with parameter customisation.
By applying a set of filters, we were able to delin-
eate a unique set of six druggable proteins with no close 
homologs in humans (and its microbiome) and that are 
of interest for drug discovery. One of them, FabI partici-
pates in fatty acid synthesis (FAS) processes. The pro-
teins of this pathway, such as FabA, FabB, FabD, FabI, 
and FabH, have an essential role during the biosynthesis 
of phospholipid membranes, lipoproteins, and LPS and 
represent attractive targets due to the structural dif-
ferences between the human and bacterial proteins.(23) 
With two commercially available inhibitors, triclosan 
and isoniazid (a first-line antituberculosis drug), FabI 
was the favorite target for antimicrobial efforts target-
ing FAS(24) and was previously proposed as an attractive 
target to combat K. pneumoniae.(11) Another druggable 
protein found in Bb is FolA which provides the main di-
hydrofolate reductase activity in the tetrahydrofolate or 
vitamin B9 pathway. The enzyme catalyses dihydrofo-
late the reduction to tetrahydrofolate via hydride trans-
fer from NADPH to C6 of the pteridine ring. Tetrahydro-
folate is an important intermediate in the biosynthesis of 
proteins and nucleic acids, it is biosynthesised de novo 
by bacteria and is involved in important biosynthesis 
pathways such as methionine, purines, thymidylate, and 




















































































































































































































































































































































































































































































































































































































































pantothenate. Humans are entirely dependent on nutri-
tional sources of folate, transforming it into an essential 
vitamin. Because dihydrofolate reductase is essential 
for cell division and growth, it is an attractive target for 
drug development. Antimicrobial agents against FolA, 
such as 5-substituted-2, 4-diaminopyrimidine (TMP), 
are widely used to treat Streptococcus pyogenes, S. 
pneumoniae, Escherichia coli, and K. pneumoniae in-
fections.(25) Additionally, the use of sulfonamide, such as 
sulfamethoxazole (SMZ), a potent and selective inhibi-
tor against another key enzyme of folate biosynthesis 
(dihydropteroate synthase) together with TMP, is used 
for certain infections treatment of since their combina-
tion causes a synergistic effect, resulting in a dramatic 
enhancement in antibacterial activity.(26) The finding of 
FabI and FolA proteins in our work contributes towards 
validating our methodological approach.
The protein product of aroA, 3-Phosphoshikimate-
1-carboxyvinyltransferase (EPSP synthase), is another 
target identified through our prioritisation pipeline. This 
protein participates in the biosynthesis of aromatic ami-
no acids, siderophores, and metabolites such as folate, 
ubiquinone and vitamin K. EPSP synthase is involved 
in the 6th step of the chorismate pathway, catalysing 
the transfer of the enolpyruvoyl moiety from phospho-
enolpyruvate to the hydroxyl group of carbon 5 of shi-
kimate 3-phosphate with the phosphate elimination to 
produce 5-enolpyruvoyl shikimate 3-phosphate (EPSP).
(27) The shikimate pathway is present in bacteria, fungi, 
algae, plants, and apicomplexan parasites, but is absent 
in humans.(28) Moreover, several bacterial pathogens use 
chorismate-derived siderophores as virulence factors. 
Inhibition of EPSP synthase is the basis of the widely 
used herbicide glyphosate. As widely reported, Class I 
EPSP synthases, which are present in plants and some 
bacteria (e.g. Salmonella typhimurium and E. coli), are 
inhibited at low concentrations of glyphosate.(29) Several 
properties of aroA gene product make it attractive as an 
antimicrobial target, including essentiality, druggability, 
and the lack of a human homolog.
Our analysis also revealed methylenetetrahydro-
folate-tRNA-(uracil-5-)-methyltransferase (TrmFO) 
as a promising target to combat Bb. TrmFO is a flavin 
dinucleotide (FAD) binding protein, which has been 
identified as a tRNA modification enzyme, responsible 
for the folate-dependent m5U-54 biosynthesis. In bacte-
ria, RNA modification enzymes have been reported to 
exhibit a moonlighting function associated with many 
cell processes like virulence, stress response, morphol-
ogy, growth, antibiotic susceptibility, and others.(30) The 
GidA (TrmFO) tRNA modification pathway has been 
implicated in bacterial virulence regulation as demon-
strated by diverse pathogens attenuation following the 
deletion of gidA. Furthermore, this gene deletion has 
produced defective cell growth, decreasing the growth 
by approximately 10-30% in several bacteria like S. en-
terica, P. aeruginosa, and E. coli.(31,32,33) Given that GidA 
mutation has a pleiotropic effect, affecting diverse phe-
notypic traits, including bacterial cell growth, gidA could 
be considered a novel and potential target in B. bacilli-
formis. Another attractive target found by our analysis 
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is Undecaprenyl-diphosphatase UppP. This protein has 
been reported as essential in other bacteria, however, 
in vitro analysis is required to determine its essential-
ity in B. bacilliformis. Overexpression of undecaprenyl-
diphosphatase generates resistance to bacitracin.(34) This 
enzyme has been studied in-silico as a druggable mo-
lecular target in Streptococcus suis(35) and Clostridium 
botulinum.(36) We have found that this protein harbors a 
set of features that defines a promising target to be used 
for drug development for B. bacilliformis; regarding it as 
a potential target of new targeted drugs to destabilise the 
cell wall to disrupt bacteria growth.
The protein product of murE, the UDP-N-acetyl-
muramoyl-L-alanyl-D-glutamate-L-lysine/2,6-dia-
minopimelate ligase, is a bacterial enzyme belonging to 
the ATP-dependent Mur ligases, which are essential for 
peptidoglycan (PG) synthesis. PG is a key component of 
the cell wall of almost all eubacteria, it is responsible for 
rigidity and shape of bacterial cells, serves as a platform 
for anchoring other cell envelope components and is es-
sential for growth and survival of bacteria. The enzymes 
that catalyse PG are considered one of the best sources 
of antibacterial targets. Similar to the other Mur class 
enzymes, MurE has been targeted in efforts to produce 
novel antimicrobials. Different chemical compounds are 
being studied taking into account their SAR (structural-
activity relationship) studies and inhibitory potential. 
Such is the case of hyperenone A which is obtained from 
hexane and chloroform extracts of the different aerial 
parts of plant Hypericum acmosepalum and quinolone 
derivatives as the novel N-methyl-2-alkenyl-4-quinolone 
are capable to inhibit MurE ligase of M. tuberculosis and 
Methicillin-resistant S. aureus (MRSA).(37)
With regards to the cellular compartment where these 
candidates are found, most of the top-ranked proteins are 
located either in the cytoplasm or in the cell membrane 
and are a priori unavailable for external binding. This 
apparent inappropriateness of cytoplasmic proteins to 
serve as a target should not hamper their further explo-
ration, as it is well-known that many antibiotics are ca-
pable of efficiently crossing bacterial membranes (either 
by diffusion or through porin channels),(38) coupled with 
recent developments of delivery strategies including the 
use of siderophores, cyclodextrins, metal nanoparticles, 
antimicrobial/cell-penetrating peptides and fusogenic li-
posomes.(39) Thus, the fact that a candidate target locates 
cytoplasmically should not detain the future design of 
antibacterial drugs directed towards their inhibition.
Further studies are warranted to follow-up experi-
mentally on our elicited targets, and we invite the scien-
tific community dedicated to this subject to help pursue 
these goals, thus strengthening the ongoing fight against 
pathogenic bacteria.
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